Characterization of chronic myeloid leukemia stem cells

Area of Science:

• Hematology
• Cancer Biology
• Stem Cell Biology

Background:

• Tyrosine kinase inhibitors have improved chronic myeloid leukemia (CML) treatment but are not curative.
• Leukemia stem cells (LSCs) are implicated in CML treatment resistance.
• The expression of potential therapeutic targets in CML LSCs is largely unknown.

Purpose of the Study:

• To identify and characterize CML LSCs.
• To analyze the expression of candidate therapeutic targets in CML LSCs.
• To determine the suitability of potential targets for CML therapy.

Main Methods:

• Isolation of CD34(+) stem/progenitor cells from normal donors and CML patients.
• Characterization of cell subsets based on immunodeficient mouse engraftment capacity.
• Analysis of candidate target gene expression (PROTEINASE 3, SURVIVIN, hTERT, PRAME, WT1) using flow cytometry and quantitative PCR.

Main Results:

• Aldehyde dehydrogenase (ALDH) activity enriched for CML stem cells (CD34(+)CD38(-)ALDH(high)) with high engrafting capacity.
• PROTEINASE 3, SURVIVIN, and hTERT showed low expression in CML LSCs, similar to normal stem cells.
• PRAME and WT1 were highly expressed in CML CD34(+) subsets compared to normal counterparts, suggesting they are promising targets.

Conclusions:

• ALDH activity is a reliable marker for enriching CML stem cells.
• The expression profile of CML LSCs differs significantly from normal stem/progenitor cells.
• PRAME and WT1 represent promising therapeutic targets for CML, while PROTEINASE 3, SURVIVIN, and hTERT are less suitable.